Business
Half Yearly Report to 31 March 2016
Half Yearly Report to 31 March 2016.
About this update from Ixico Plc
[{"type":"text","content":"\n \nRNS Number : 3470A IXICO plc 07 June 2016 \n\n \n \nIXICO plc \n(\"IXICO\", the \"Company\" or the \"Group\")\n \nHalf Yearly Report to 31 March 2016\n \nContinued expansion of digital technologies and therapeutic areas focused on brain health \n \nDelivering on new contracts including Parkinson's disease and multiple sclerosis \n \n7 June 2016, IXICO plc (AIM: IXI), the brain health company, announces its unaudited interim results for the six months ended 31 March 2016.\n \nPeriod Highlights\n· Assessa® partnership deal with a leading pharmaceutical company to improve the risk profile of a globally marketed multiple sclerosis drug\n· Four new contracts in Alzheimer's disease clinical trials with a combined value of over £3.0m \n· Acquisition of Optimal Medicine Limited and associated equity fundraising of £2.7m (gross)\no mehealth® technology deployed in the American Academy of Pediatrics 2016 Quality Improvement Program \no Integration of the Optimal Medicine business and products progressing well\n· Financial performance reflects start-up of a major new clinical trial and digital healthcare contracts \no Total income (revenue plus other income) of £2.0m (2015: £2.0m)\no Operating loss of £1.1m (2015: £0.8m) including investment in digital technology platform and pharma digital health relationships\no Loss per share 4.6p (2015: 4.1p) \no Strengthened balance sheet with cash of £3.2m (2015: £1.9m) \n \nPost-Period Highlights\n· First contract in Parkinson's disease with Oxford Biomedica\n· Joined seven global pharmaceutical companies in the Critical Path for Parkinson's consortium \n· Deployment of mehealth® technology in Cygnus project, part of the Dementia Platform UK consortium \n \nDerek Hill, Chief Executive Officer of IXICO, said:\n\"We continue to demonstrate our deep expertise in brain health and the value of IXICO's technology platform through winning four new contracts in Alzheimer's disease while further expanding our brain health focus into new therapeutic areas with contract wins for multiple sclerosis and Parkinson's disease. Through i...